BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24423476)

  • 1. Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization.
    Owens CD; Gasper WJ; Walker JP; Alley HF; Conte MS; Grenon SM
    J Vasc Surg; 2014 Apr; 59(4):1016-24. PubMed ID: 24423476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results From the DANCE Clinical Trial.
    Razavi MK; Donohoe D; D'Agostino RB; Jaff MR; Adams G;
    JACC Cardiovasc Interv; 2018 May; 11(10):921-931. PubMed ID: 29730377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System: 12-Month Results From the TOBA II Study.
    Gray WA; Cardenas JA; Brodmann M; Werner M; Bernardo NI; George JC; Lansky A
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2375-2384. PubMed ID: 31806218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospective Evaluation of the TIGRIS Vascular Stent Within a Modern Treatment Algorithm.
    Werner M; Gomari-Grisar F; Belalcazar S; Hirschl M; Kalchhauser G; Al-Taiee B; Jäger N; Westhausser C; Tischler M; Tischler R
    J Endovasc Ther; 2019 Oct; 26(5):637-642. PubMed ID: 31303096
    [No Abstract]   [Full Text] [Related]  

  • 9. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
    Zeller T; Brechtel K; Meyer DR; Noory E; Beschorner U; Albrecht T
    J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial.
    Jongsma H; van Mierlo-van den Broek P; Imani F; van den Heuvel D; de Vries JPM; Fioole B
    J Vasc Surg; 2017 Oct; 66(4):1293-1298. PubMed ID: 28826727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the femoropopliteal artery with the bioresorbable REMEDY stent.
    Bontinck J; Goverde P; Schroë H; Hendriks J; Maene L; Vermassen F
    J Vasc Surg; 2016 Nov; 64(5):1311-1319. PubMed ID: 27462002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention.
    Armstrong EJ; Singh S; Singh GD; Yeo KK; Ludder S; Westin G; Anderson D; Dawson DL; Pevec WC; Laird JR
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1168-74. PubMed ID: 23630047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.
    Shammas NW; Shammas GA; Banerjee S; Popma JJ; Mohammad A; Jerin M
    J Endovasc Ther; 2016 Apr; 23(2):339-46. PubMed ID: 26921281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
    JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia.
    Lichtenberg M; Stahlhoff W; Boese D
    J Cardiovasc Surg (Torino); 2013 Aug; 54(4):433-9. PubMed ID: 24013531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.